About The Cover
Figure 2 in Chow & Baker outlines a framework for translational research using genetically engineered mouse models (GEMMs) for high-grade astrocytoma (HGA).
Table of Contents
Editorial Comments
| Histone code, human growth and cancer |
| Francesco Crea |
| 1-2 |
| PDF HTML |
| Histone modification defects in developmental disorders and cancer |
| Nicholas CP Cross |
| 3-4 |
| PDF HTML |
| Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1 |
| Suhwan Chang, and Shyam K. Sharan |
| 5-6 |
| PDF HTML |
| The Safety of Embryonic Stem Cell Therapy Relies on Teratoma Removal |
| Chad Tang, Irving L. Weissman, and Micha Drukker |
| 7-8 |
| PDF HTML |
Reviews
| microRNA-1/133a and microRNA-206/133b clusters: Dysregulation and functional roles in human cancers |
| Nijiro Nohata, Toyoyuki Hanazawa, Hideki Enokida, and Naohiko Seki |
| 9-21 |
| Abstract PDF HTML Supplementary Files |
Brief Reports
| Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells |
| Max Schlaak, Patrick Schmidt, Christopher Bangard, Peter Kurschat, Cornelia Mauch, and Hinrich Abken |
| 22-30 |
| Abstract PDF HTML |
Research Papers
| A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer |
| Roland H. Stauber, Shirley K. Knauer, Negusse Habtemichael, Carolin Bier, Britta Unruhe, Simona Weisheit, Stephanie Spange, Frank Nonnenmacher, Verena Fetz, Torsten Ginter, Sigrid Reichardt, Claus Liebmann, Günter Schneider, and Oliver H. Krämer |
| 31-43 |
| Abstract PDF HTML Supplementary Files |
| Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma |
| Hideo Hidaka, Naohiko Seki, Hirofumi Yoshino, Takeshi Yamasaki, Yasutoshi Yamada, Nijiro Nohata, Miki Fuse, Masayuki Nakagawa, and Hideki Enokida |
| 44-57 |
| Abstract PDF HTML Supplementary Files |
| “Picolog,” a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo |
| Brian A. DeChristopher, Alice C. Fan, Dean W. Felsher, and Paul A. Wender |
| 58-66 |
| Abstract PDF HTML |
Research Perspectives
| Capturing the Molecular and Biological Diversity of High-Grade Astrocytoma in Genetically Engineered Mouse Models |
| Lionel M.L. Chow, and Suzanne J. Baker |
| 67-77 |
| Abstract PDF HTML |
| Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer |
| Helen M. Coley, Eleftheria Hatzmichael, Sarah P. Blagden, Iain A. McNeish, Alastair Thompson, Tim Crook, and Nelofer Syed |
| 78-83 |
| Abstract PDF HTML |
| Recent Developments in Targeting Carbonic Anhydrase IX for Cancer Therapeutics |
| Paul C. McDonald, Jean-Yves Winum, Claudiu T. Supuran, and Shoukat Dedhar |
| 84-97 |
| Abstract PDF HTML |
| Neoplastic cells are a rare component in human glioblastoma microvasculature |
| Fausto J. Rodriguez, Brent A. Orr, Keith L. Ligon, and Charles G. Eberhart |
| 98-106 |
| Abstract PDF HTML |
| Curtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatment |
| Navjotsingh Pabla, and Zheng Dong |
| 107-111 |
| Abstract PDF HTML Supplementary Files |
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Impact Journals LLC 2008